Entera Bio Ltd. plans to submit the final Phase 3 protocol for EB613 to the FDA in Q1 2026 after a ruling on December 19th, 2025. A Phase 1 bridging study for Next-Generation EB613 is progressing with results expected in Q1 2026. The company also aims to accelerate its hypoparathyroidism program with lead long-acting PTH variants. Strategic partnership discussions are ongoing across the pipeline to optimize development and commercialization. Entera Bio focuses on developing oral peptide and protein replacement therapies for unmet medical needs, with a strong emphasis on women-centric conditions like osteoporosis and hypoparathyroidism.

Read more at GlobeNewswire: Entera Bio Announces Upcoming Q1 2026 Corporate Priorities